Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avenue TherapeuticsATXI +11.85%29 Equity-to-Asset is 0.29 as of Jun. 2026, which is 60% below its 10-year median of 0.73. GuruFocus rates ATXI with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,414 Biotechnology companies, Avenue Therapeutics ranks worse than 78.93% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avenue Therapeutics Equity-to-Asset Related Terms
Avenue Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATXI vs ABPO, BBLG, SCNI: Equity-to-Asset Comparison
For the Biotechnology subindustry, Avenue Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avenue Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a Equity-to-Asset of 0.29 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avenue Therapeutics and its competitors. This is 60% below median its historical median of 0.73. According to the industry distribution chart, Avenue Therapeutics ranks #1116 out of 1414 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Avenue Therapeutics' Equity-to-Asset too high?
Avenue Therapeutics' current Equity-to-Asset of 0.29 is 60% below median its 10-year median of 0.73. The Biotechnology industry median Equity-to-Asset is 0.68. Avenue Therapeutics' value of 0.29 is 57.4% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #1116 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' Equity-to-Asset compare to ABPO and BBLG?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #1116 out of 1414 companies for Equity-to-Asset. This places Avenue Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Avenue Therapeutics' value of 0.29 is 57.4% below this benchmark. While the company's 10-year median is 0.73 vs. the industry median of 0.68, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current Equity-to-Asset of 0.29 is 57.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avenue Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current Equity-to-Asset is 0.29, which is 60% below median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current Equity-to-Asset of 0.29. The current Equity-to-Asset is 0.29, which is 60% below median its 10-year median of 0.73 and 57.4% below the Biotechnology industry median of 0.68. Avenue Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Equity-to-Asset is 0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
29GF Score
Get the complete analysis for ATXI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
